Clinical Trials
Schizophrenia
Featured Studies
Featured studies include only those currently recruiting participants. They are listed according to the date they were added to the ClinicalTrials.gov registry, with the most recent studies appearing first.
- Examining Risk Factors for Atypical Antipsychotic Metabolic Side Effects.
Interventional study. This study will examine possible causes of metabolic side effects in people taking atypical antipsychotic (AAP) medications. Ages 18-90. Location in Ann Arbor, MI.
- Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia.
Interventional study. This study will compare the safety and effectiveness of three different antipsychotic medications, as well as the use of other medications to limit treatment side effects, in adults with schizophrenia. Ages 18-40. Locations in Colton, CA; Palo Alto, CA; New Haven, CT; Miami, FL; Augusta, GA; Worcester, MA; Glen Burnie, MD; Detroit, MI; Minneapolis, MN; Butner, NC; New York, NY; Dallas, TX; Houston, TX; Milwaukee, WI.
- Transcranial Direct Current Brain Stimulation to Treat Patients With Childhood-Onset Schizophrenia.
Interventional study. This study will test whether transcranial direct current stimulation (TDCS) can be used safely in children with schizophrenia and if it can improve memory and attention span or auditory hallucinations in these children, at least temporarily. Ages 10 and over. Location in Bethesda, MD.
- Effectiveness of Neuroadaptive Cognitive Training in Adolescents at Risk for Psychosis.
Interventional study. This study will evaluate the effectiveness of intensive computerized cognitive training in preventing the onset of psychotic disorder and improving adaptive functioning in adolescents at high risk of schizophrenia. Ages 16-25. Locations in Davis, CA; San Francisco, CA.
- Effectiveness of Vitamin Supplementation in Treating People With Residual Symptoms of Schizophrenia.
Interventional study. This study will evaluate the effectiveness of folate and B12 supplementation in reducing negative symptoms in people with schizophrenia. Ages 18-68. Locations in Boston, MA; Grand Rapids, MI; Rochester, NY.
- Social Cognition and Interaction Training for Improving Social Functioning in People With Schizophrenia.
Interventional study. This study will determine the effectiveness of social cognition and interaction training, a manual-based group therapy program, in helping people with schizophrenia improve their social cognition and social functioning. Ages 18-65. Location in Chapel Hill, NC.
- Effects of Motivating People With Schizophrenia to Exercise.
Interventional study. This study will evaluate the impact of motivational guidance to exercise on people with schizophrenia, based on their participation in a walking program. Ages 22 and over. Location in Knoxville, TN.
- The Effects of Atomoxetine on Cognition and Brain Function Based on COMT Genotype.
Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-45. Location in Bethesda, MD.
- A Self-Management Program for Adults With Both Schizophrenia and a Co-Occurring Medical Condition.
Interventional study. This study will develop and evaluate the effectiveness of a self-management program for adults living with both schizophrenia and a co-occurring medical condition. Ages 18-64. Location in Baltimore, MD.
- The Use of Galantamine and CDP-Choline to Treat Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of galantamine and CDP-choline in improving symptoms associated with schizophrenia. Ages 18-70. Location in Washington, DC.
- Effectiveness of Tropisetron Plus Risperidone for Improving Cognitive and Perceptual Disturbances in Schizophrenia.
Interventional study. This study will determine the effectiveness of tropisetron plus risperidone in improving cognitive and perceptual disturbances and symptoms in Chinese people with schizophrenia. Ages 18-64. Locations in Beijing, China; Houston, TX.
- Comparison of Video Consent Versus Routine Consent for Participation in Research Studies.
Interventional study. The purpose of this study is to examine a novel technique for improving the informed consent process for participation in research by the older psychiatric population. Ages 40 and over. Location in San Diego, CA.
- Comparison of Antipsychotics for Metabolic Problems in the Treatment of People With Schizophrenia or Schizoaffective Disorder.
Interventional study. The study will compare the effectiveness of antipsychotic medications for patients with schizophrenia or schizoaffective disorder for whom a medication change may be indicated because of an increased risk of cardiovascular disease. Ages 18-65. Locations in Colton, CA; Orange, CA; Palo Alto, CA; San Diego, CA; Farmington, CT; New Haven, CT; Boca Raton, FL; Miami, FL; Atlanta, GA; Augusta, GA; Iowa City, IA; Wichita, KS; Shreveport, LA; Boston, MA; Fall River, MA; Worcester, MA; Glen Burnie, MD; Detroit, MI; Minneapolis, MN; St. Louis, MO; Butner, NC; Chapel Hill, NC; Charlotte, NC; Albuquerque, NM; New York, NY; Rochester, NY; Cincinnati, OH; Philadelphia, PA; Conroe, TX; Dallas, TX; Houston, TX; San Antonio, TX; Tacoma, WA; Milwaukee, WI.
- Improving Adherence to Oral Antipsychotic Medications in People With Schizophrenia.
Interventional study. This study will determine the comparative effectiveness of two systems designed to improve medication adherence in people with schizophrenia. Ages 18-60. Location in San Antonio, TX.
- Improving Medication Adherence Among People With Schizophrenia Through the Use of 2-Way Pagers.
Interventional study. This study will determine whether using a pager improves medication adherence in people with schizophrenia. Ages 18 and over. Location in Glen Oaks, NY.
- Attention Shaping Procedures for Improving Psychosocial Skills Among Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of attention shaping procedures in improving attentiveness and learning abilities in people undergoing psychosocial skills training treatment for schizophrenia. Ages 18-55. Locations in Monmouth Junction, NJ; New Brunswick, NJ.
- Measuring Smoking Behavior in People With Schizophrenia and Bipolar Disorder.
Evaluation study. This study will evaluate the differences in smoking behavior, nicotine intake, and nicotine boost among people with schizophrenia, bipolar disorder, or no mental illness. Ages 18-75. Location in New Brunswick, NJ.
- Culturally Based Family Therapy for Improving Treatment Outcome for People With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of a culturally based family therapy intervention in improving treatment outcome in people with schizophrenia. Ages 13 and over. Location in Coral Gables, FL.
- Guanfacine for Improving Cognitive Symptoms in People With Schizotypal Personality Disorder.
Interventional study. This study will determine the effectiveness of guanfacine in improving symptoms of schizotypal personality disorder. Ages 18-60. Location in New York, NY.
- Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia.
Interventional study. This study will evaluate the effects of combination treatment with aripiprazole and clozapine on insulin resistance, blood fat levels, and weight gain in people with schizophrenia. Ages 18-65. Location in Boston, MA.
- Effectiveness of a Lifestyle Intervention for Increasing Physical Activity in Adults With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of a lifestyle intervention in increasing physical activity and reducing disease symptoms in sedentary adults with schizophrenia. Ages 21-64. Location in La Jolla, CA.
- Ziprasidone for Improving Insulin Sensitivity in People With Schizophrenia Who Are at Risk for Diabetes.
Interventional study. This study will evaluate the effectiveness of ziprasidone treatment versus treatment with a standard atypical antipsychotic drug in improving insulin sensitivity and reducing excess abdominal fat storage in people with schizophrenia who are at risk for diabetes. Ages 18-65. Location in San Diego, CA.
- Cognitive Behavioral Social Skills Training for Improving Social Functioning in People With Schizophrenia.
Interventional study. This study will evaluate the effectiveness of cognitive behavioral social skills training versus supportive contact in improving social functioning in people with schizophrenia. Ages 18 and over. Location in San Diego, CA.
- Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia.
Interventional study. This study will determine the effectiveness of various combinations of psychosocial therapy and risperidone treatment in improving work or school performance in people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.
- Oral Versus Injectable Risperidone for Treating First-Episode Schizophrenia.
Interventional study. This study will determine the effectiveness of oral risperidone versus long-acting injectable risperidone in treating people with first-episode schizophrenia. Ages 18-45. Location in Los Angeles, CA.
- Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared To Injectables: Evaluating Efficacy.
Interventional study. This study is designed to find out whether taking antipsychotic medication once every two weeks by injection compared to taking daily oral medication will help people with schizophrenia maintain better control of their symptoms. Ages 18-65. Locations in Los Angeles, CA; Augusta, GA; Iowa City, IA; Boston, MA; Fall River, MA; Omaha, NE; Albuquerque, NM; Glen Oaks, NY.
- Comparison of Aripiprazole and Risperidone for the Treatment of People With First-Episode Psychosis.
Interventional study. This 52 week long study evaluates the effectiveness of aripiprazole versus risperidone in treating people with first-episode schizophrenia. Ages 15-40. Locations in Newark, NJ; Bronx, NY; Brooklyn, NY; Glen Oaks, NY; Jamaica, NY; Manhasset, NY; Staten Island, NY; San Antonio, TX.
- Effectiveness of Targeted Cognitive Training for Neurological Deficits in People With Schizophrenia.
Interventional study. This study will determine the effectiveness of reward-intensive, computer-based targeted cognitive training in improving neurocognitive deficits in people with schizophrenia. Ages 18-60. Location in San Francisco, CA.
- Transcranial Magnetic Stimulation for "Voices".
Interventional study. This study will determine the efficacy of MRI-guided transcranial magnetic stimulation (TMS)in reducing "voices" and other symptoms experienced by people with schizophrenia and schizoaffective disorder. Ages 18-55. Location in New Haven, CT.
- Graduated Recovery Intervention Program for Enhancing Treatment for First-Episode Psychosis.
Interventional study. This study will determine the effectiveness of the Graduated Recovery Intervention Program, a manual-based individual therapy program, in enhancing the clinical benefit of routine treatment for individuals recovering from their first episodes of psychosis. Ages 18 and over. Location in Chapel Hill, NC.
- Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients.
Interventional study. This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia. Ages 18-60. Location in Denver, CO.
- Side Effects of Newer Antipsychotics in Older Adults.
Interventional study. This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals. Ages 40 and over. Location in San Diego, CA.
- D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia.
Interventional study. This study will examine the effectiveness of D-serine in increasing and sustaining the benefits of cognitive retraining in people with schizophrenia. Ages 18-65. Location in Bangalore, India.
- Determining Metabolic Effects of Valproate and Antipsychotic Therapy.
Interventional study. This study will determine the metabolic processes responsible for high levels of blood glucose, metabolism disorders, and weight gain in people with schizophrenia who have been treated with antipsychotic medications in combination with valproate. Ages 18-60. Location in St. Louis, MO.
- Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia.
Interventional study. This study will assess the effectiveness of pimozide in enhancing the effects of clozapine in the treatment of schizophrenia. Ages 18-65. Locations in New York, NY; W. Brentwood, NY.
- Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia.
Interventional study. This study will examine the effects of ondansetron on auditory nerve activity in people with schizophrenia who are being treated with new antipsychotics. Ages 18-55. Location in Denver, CO.
- Treatment Response to Rehabilitation in Patients With Schizophrenia.
Evaluation study. This study will examine the ways in which schizophrenia-related symptoms affect response to a rehabilitation program for people with schizophrenia. Ages 18 and over. Location in Hartford, CT.
- Effects of Modafinil on Brain Function in Patients With Schizophrenia.
Interventional study. This study will evaluate whether modafinil improves cognition in patients with schizophrenia and healthy volunteers. Ages 18-60. Location in Bethesda, MD.
- Risperidone Treatment in Schizophrenia Patients Who Are Currently Taking Clozapine.
Interventional study. This study will determine whether adding the drug risperidone (Risperdal®) is more effective than placebo in treating schizophrenic patients who are taking the drug clozapine. Ages 18-65. Location in Baltimore, MD.
- Screening for Childhood-Onset Psychotic Disorders.
Evaluation study. The purpose of this study is to screen and evaluate children with psychotic disorders to establish or confirm their diagnosis and to collect data about their condition. Ages 5-18. Location in Bethesda, MD.
- Treating Drug-Resistant Childhood Schizophrenia.
Interventional study. This study will compare clozapine and olanzapine (Zyprexa®) for the treatment of children and adolescents who have failed standard antipsychotic treatment for schizophrenia. Ages 10-18. Locations in Bronx, NY; Dix Hills, NY; Glen Oaks, NY.
- Clinical Trial of Tolcapone for Cognition in Schizophrenia.
Interventional study. This study will evaluate whether Atomoxetine improves cognition in healthy volunteers as well as patients with schizophrenia. Ages 18-60. Location in Bethesda, MD.
- Molecular Genetics of Schizophrenia.
Evaluation study. This study will create a DNA collection with blood samples from families with at least two siblings who have schizophrenia symptoms. Ages 18 and over. Locations in Brisbane, Australia; Irvine, CA; Denver, CO; Atlanta, GA; Iowa City, IA; Evanston, IL; New Orleans, LA; St. Louis, MO; New York, NY; Philadelphia, PA.
- Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers.
Evaluation study. The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Ages 18 and over. Location in Bethesda, MD.
- Evaluation of the Genetics of Bipolar Disorder.
Evaluation study. This study looks to identify genes that may affect a person's chances of developing bipolar disorder (BP) and related conditions. Ages 18 and over. Locations in La Jolla, CA; Orange, CA; Washington, DC; Iowa City, IA; Chicago, IL; Indianapolis, IN; Louisville, KY; Baltimore, MD; Detroit, MI; St. Louis, MO; Stonybrook, NY; Philadelphia, PA.
- Evaluating Genetic Risk Factors for Childhood-Onset Schizophrenia.
Evaluation study. A study of children and adolescents (current N=48) with very early onset by age 12 (COS) of DSM-III-R defined schizophrenia with (97-M-0126) is examining the clinical, neurobiological, early neurodevelopmental, genetic, and clinical drug response characteristics of these cases. Ages 6-70. Location in Bethesda, MD.
- Inpatient Evaluation of Adults With Schizophrenia.
Evaluation study. The purpose of this study is to understand the biologic basis of schizophrenia and to determine which symptoms are related to the illness itself and which are related to medications used to treat the illness. Ages 18 and over. Location in Bethesda, MD.
- Studies of Frontal Lobe Brain Functioning in Schizophrenia.
Evaluation study. The purpose of this study is to use brain imaging technology to investigate the role of the frontal lobe of the brain in the thinking of individuals with schizophrenia and other neuropsychiatric disorders and healthy volunteers. Ages 18-90. Location in Bethesda, MD.
- Brain Tissue Collection for Neuropathological Studies.
Evaluation study. The purpose of this study is to collect and study the brain tissue of deceased individuals to learn more about the nervous system and mental disorders. Locations in Washington, DC; Bethesda, MD; Fairfax, VA.
- Magnetic Resonance Imaging (MRI) of Neuropsychiatric Patients and Healthy Volunteers.
Evaluation study. The purpose of this study is to use brain imaging technology to compare differences in brain structure, chemistry, and functioning in individuals with brain and mental disorders compared to healthy volunteers. Ages 18 and over. Location in Bethesda, MD.
- Genetic Study of Schizophrenia.
Evaluation study. This large ongoing study at NIMH investigates the neurobiology of schizophrenia by identifying susceptibility genes, evaluating their impact on brain function to better understand how to treat and prevent this illness. Ages 18 and over. Location in Bethesda, MD.
- Electrophysiology and Blood Flow in Patients With Schizophrenia and Their Siblings.
Evaluation study. This study will explore how the brain works during memory testing in an effort to understand why some patients with schizophrenia have memory difficulties. Ages 18-55. Location in Bethesda, MD.
Search ClinicalTrials.gov for other NIH studies on Schizophrenia.
